search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Pharmacokinetic study of enzalutamide and cabazitaxel combination therapy


- candidate number21924
- NTR NumberNTR5164
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR9-apr-2015
- Secondary IDsNL51749.078.14 2014-005150-19
- Public TitlePharmacokinetic study of enzalutamide and cabazitaxel combination therapy
- Scientific TitlePharmacokinetic study of enzalutamide and cabazitaxel combination therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients
- ACRONYMCabenza-study
- hypothesisSince cabazitaxel will increasingly substitute docetaxel in the setting of mCRPC , it is important to investigate whether cabazitaxel PK is significantly and clinically relevantly influenced by enzalutamide treatment, especially after more than 3 weeks of concomitant use. Cabazitaxel is also extensively metabolized by CYP3A4 and it is expected that this drug is prone to drug-drug interactions with CYP3A inducing co-medication (like enzalutamide). In this study we therefore investigate the pharmacokinetics (PK) and safety of cabazitaxel concomitantly used with enzalutamide in men with mCRPC.
- Healt Condition(s) or Problem(s) studiedMetastatic castrate-resistant prostate cancer (mCRPC)
- Inclusion criteria1. Age: >=18 years
2. Histological or cytological confirmed diagnosis of mCRPC
3. ECOG Performance Status °‹ 1
4. Written informed consent according to ICH-GCP prior to screening evaluations
5. Patients who are, as per local protocol, eligible for treatment with standard of care cabazitaxel
6. Adequate organ function as defined by:
a. Total bilirubin °‹ 1.5 x ULN (except in case of documented Gilbert°Įs disease)
b. ASAT °‹ 2.5 x ULN (or °‹ 5 x ULN if liver metastases are present)
c. ALAT °‹ 2.5 x ULN (or °‹ 5 x ULN if liver metastases are present)
d. Serum creatinin °‹ 1.5 x ULN
- Exclusion criteria1. Evidence of central nervous system disease
2. History of seizure or any condition predisposing to seizure
3. Use of concomitant medication predisposing to seizure
4. Use of (over the counter) medication or (herbal) supplements which can interact with either cabazitaxel or enzalutamide, e.g. by induction or inhibition of CYP3A4, CYP2C9 and CYP2C19
5. Unable or unwilling to abstain from grapefruit, grapefruit juice, herbal dietary supplements, and herbal tea during the study
6. Previous use of enzalutamide during the last 6 weeks prior to cabazitaxel treatment
7. Contraindications for use of enzalutamide
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupCrossover
- TypeSingle arm
- Studytypeintervention
- planned startdate 8-apr-2015
- planned closingdate1-nov-2017
- Target number of participants14
- InterventionsCabazitaxel will be used as standard of care treatment. Enzalutamide is also registered for treatment of mCRPC, but in this study it will be administered solely for investigational purpose.
- Primary outcomeTo determine the influence of enzalutamide on cabazitaxel AUC compared to cabazitaxel alone in mCRPC patients.
- Secondary outcome1. To evaluate the incidence and severity of side-effects of treatment with enzalutamide in absence and presence of cabazitaxel.
2. Other pharmacokinetic outcomes (i.e. clearance, maximum concentration (Cmax) and time of Cmax (tmax))
- Timepointsn.a.
- Trial web siten.a.
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESProf. dr. Ron Mathijssen
- CONTACT for SCIENTIFIC QUERIESPhD-student Roelof van Leeuwen
- Sponsor/Initiator Erasmus MC Cancer Institute, department of Medical Oncology
- Funding
(Source(s) of Monetary or Material Support)
Astellas Pharma B.V
- Publicationsn.a.
- Brief summarySince cabazitaxel will increasingly substitute docetaxel in the setting of mCRPC , it is important to investigate whether cabazitaxel PK is significantly and clinically relevantly influenced by enzalutamide treatment, especially after more than 3 weeks of concomitant use. Cabazitaxel is also extensively metabolized by CYP3A4 and it is expected that this drug is prone to drug-drug interactions with CYP3A inducing co-medication (like enzalutamide). In this study we therefore investigate the pharmacokinetics (PK) and safety of cabazitaxel concomitantly used with enzalutamide in men with mCRPC.
- Main changes (audit trail)
- RECORD9-apr-2015 - 16-nov-2017


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl